[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Kwon et al., 2019 - Google Patents

Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: a multicenter study …

Kwon et al., 2019

Document ID
2509635540800786793
Author
Kwon J
Yoo S
Nam S
Kim H
Kim C
You C
Choi S
Cho S
Han J
Song D
Chang U
Yang J
Lee S
Lee H
Han N
Kim S
Song M
Sung P
Jang J
Bae S
Choi J
Yoon S
Publication year
Publication venue
Journal of Medical Virology

External Links

Snippet

Background A real‐life study is essential outside clinical trials. The aim is to evaluate the clinical outcomes of direct acting agents (DAA) for patients with chronic hepatitis C (CHC) in real practice. Methods We analyzed 590 consecutively enrolled patients with CHC‐1b who …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriphage
    • C12Q1/701Specific hybridization probes
    • C12Q1/706Specific hybridization probes for hepatitis
    • C12Q1/707Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/576Immunoassay; Biospecific binding assay for hepatitis
    • G01N33/5767Immunoassay; Biospecific binding assay for hepatitis non-A, non-B hepatitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines

Similar Documents

Publication Publication Date Title
Yoshimi et al. Long term persistence of NS5A inhibitor‐resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy
Agarwal et al. Safety and efficacy of vesatolimod (GS‐9620) in patients with chronic hepatitis B who are not currently on antiviral treatment
Chan et al. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B
Asselah et al. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1‐6 and compensated cirrhosis or advanced fibrosis
Miyaki et al. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients
Wong et al. Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease
El‐Khayat et al. Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C‐related cirrhosis, genotype 4
Mücke et al. No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct‐acting antivirals for hepatitis C in a large real‐world cohort
Papatheodoridis et al. Hepatocellular carcinoma risk in HB eAg‐negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet. Greece cohort
Kosaka et al. Emergence of resistant variants detected by ultra‐deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1
Moucari et al. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C
Goel et al. Daclatasvir and reduced‐dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate< 30 mL/min
Itakura et al. Naturally occurring, resistance‐associated hepatitis C virus NS5A variants are linked to interleukin‐28B genotype and are sensitive to interferon‐based therapy
Mizokami et al. Resistance analyses of Japanese hepatitis C‐infected patients receiving sofosbuvir or ledipasvir/sofosbuvir containing regimens in phase 3 studies
Ueno et al. Prevention of hepatocellular carcinoma complicating chronic hepatitis C
Ahn et al. A phase 3b study of sofosbuvir plus ribavirin in treatment‐naive and treatment‐experienced Korean patients chronically infected with genotype 2 hepatitis C virus
Uchida et al. Development of rare resistance‐associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two‐hit mechanism
Vassiliadis et al. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine‐resistant HBeAg‐chronic hepatitis B patients: A 4‐year study
Everson et al. Daclatasvir+ asunaprevir+ beclabuvir±ribavirin for chronic HCV genotype 1‐infected treatment‐naive patients
Kwon et al. Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: a multicenter study in Korea
Morio et al. Real‐world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus‐infected cirrhosis patients
Fourati et al. Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS 5A inhibitor
Kao et al. Twelve‐week ravidasvir plus ritonavir‐boosted danoprevir and ribavirin for non‐cirrhotic HCV genotype 1 patients: A phase 2 study
Kao et al. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis
Mushtaq et al. Direct‐acting antiviral agents in the treatment of chronic hepatitis C—Real‐life experience from clinical practices in Pakistan